ALZINOVA - Key Persons
Anders has more than 25 years of experience within international finance and business development in the pharmaceutical- and medical device industr ies. His experience includes Business- and Corporate Development from Pharmacia & Upjohn, Q-Med AB (publ), partner and CEO at venture capital firm Nexttobe AB and Executive VP and CFO at Oasmia Pharmaceutical AB (publ). In addition, Anders has extensive board experience from pharma- and tech sectors including, but not limited to, Hansa Biopharma AB (publ), Biolamina AB, Delta Projects AB, Selego AB.
Job Titles:
- Member of the Alzinova Team
- Member of the Management Team
- Chief Scientific Officer since 2015
Anders is one of Alzinova's co-founders and was also CEO of the Company during a transitional period. He has extensive experience in protein research with an emphasis on neurotoxic peptide devices. Anders has since 2007 worked with the ALZ-101 and ALZ-201 projects as its main occupation, and as chief operating officer has run much of the Company's operations since it was founded in 2011. He is also a co-inventor of Alzinova's AβCC technology and has been a deputy board member since 2011.
Anders has held several senior roles in Astra, AstraZeneca, CV Therapeutics, Actogenics and Tikomed AB. He has previous experience in management, business development, financing and pharmaceutical development.
Job Titles:
- Intellectual Property Officer
Ann-Sofie Sternås has more than 25 years of experience in IP/patent matters from the pharmaceutical industry. She has an in-depth understanding and knowledge of IP strategic matters, with a heavy focus on the US legislation, particularly IP matters in the interface between patent legislation and regulatory law. Ann-Sofie has previously worked at AstraZeneca and Pharmacia on IP-related matters from a global perspective, including more than 10 years in the IP litigation of several blockbuster drugs. She has also worked at the investment company Karolinska Development AB.
Carol is an R&D and pharmaceutical development expert with more than 30 years of experience in UK and US-based pharmaceutical and biotechnology companies focusing on drug acquisition and profiling of NCE biology. She has played a key role in GSK Biopharmaceuticals, including management in pharmaceutical research and development activities in several therapeutic areas, especially in the areas of immuno-inflammatory diseases and neuroscience with an emphasis on translational medicine. She recently managed a semi-philanthropic dementia fund with a central focus on identifying and developing new disease-modified mechanisms for the treatment of all different types of dementia. She has over 90 articles published in scientific journals. Until recently Carol was the Director of Research and Managing Director of EDoN, a global early detection initiative at Alzheimer's Research UK. She worked as Chief Medical and Scientific Officer at Small Pharma and is currently an independent biomedical consultant.
Job Titles:
- Executive Assistant & Communications since 2020
Cecilia has over 10 years of experience in the biopharma industry and more than 20 years in administration.
Job Titles:
- Board Member since 2015
- Physician at the Neurology
Clas is a physician at the Neurology clinic and at the laboratory for clinical immunology at Sahlgrenska University Hospital in Gothenburg. Since 2001 he has conducted research within Multiple Sclerosis (MS) at the hospital's Multiple sclerosis centre and the Department of Clinical Neuroscience, University of Gothenburg. In addition to academic research, he has participated in several clinical drug trials in MS led by Biogen-Idec, Merck, Novartis, Roche and Sanofi, several of which resulted in today's standard treatments for MS.
Job Titles:
- Member of the Alzinova Team
- Member of the Management Team
- Interim Chief Financial Officer since 2024
Erik has more than 25 years of experience within international finance and business administration in different sectors. His experience includes financial positions within Swedbank Robur, CFO and CEO at Dunross & Co AB, a privately owned investment company, and CEO at Reguity Group AB. Erik has also experience as interim Chief Financial Officer from several companies.
Job Titles:
- Chairman of the Board since 2023
Julian has more than 25 years of experience in finance and international business development within the pharmaceutical and technology industries including Oasmia Pharmaceutical AB. Julian is an entrepreneur who ran his own companies for many years in several different business areas, primarily pharmaceutical development. Is an active investor and through companies also a major owner in a number of listed companies.
Job Titles:
- Clinical Project Manager since 2023
Karin has over 30 years of experience in clinical R&D including clinical project and study management. She has previously worked both in large clinical organizations and in a start-up biopharma company, InDex Pharma.
Job Titles:
- Member of the Alzinova Team
- Member of the Management Team
- Chief Medical Officer since 2023
Kirsten has more than 30 years of experience in medicine, clinical studies and drug development as well as business development and bringing products to market from Lundbeck, Pfizer, ALK and Novo Nordisk, among others. She is currently CMO at SynAct Pharma and Tetra Pharm Technologies and is Medical & Compliance Manager at Sandoz.
Job Titles:
- Member of the Alzinova Team
- Member of the Management Team
- Chief Executive Officer / Verkställande Direktör
- Chief Executive Officer since 2019
Kristina has 30 years of experience in drug development from leading roles in the pharmaceutical and biopharma industry. She has previously worked at AstraZeneca with research and development in both early and late phase and has been globally responsible for marketed products. Kristina has also worked at the biopharma company Albireo AB/Pharma Inc, as VP Clinical & Regulatory Affairs and VP Global Project Head and was engaged in building the company.
Job Titles:
- Head of Regulatory Affairs since 2022
Margareth Jorvid has over 30 years of experience in Regulatory Affairs and has worked at the Swedish Medical Products Agency (MPA) as well as in local and global roles for large and small pharmaceutical companies, such as Roussel Nordiska, Hoechst Marion Roussel (Stockholm and Paris, France) and Neopharma. Since 2006, consultant in regulatory affairs and QA for pharmaceuticals, advanced therapies and medical devices through her company Methra Uppsala AB, LSM group. She is a member and honorary member of TOPRA (Organisation for Professionals in Regulatory Affairs), TOPRA Board member 2004-2012 and TOPRA President 2005-2006.
Per-Göran has 35 years of experience from the pharmaceutical industry. He has extensive experience in pharmacology and neuro-pharmacology from Kabi, Kabi Pharmacia, Pharmacia & Upjohn and Pharmacia, AstraZeneca and Albireo. Per-Göran is the founder of Albireo AB and was VP Development for Albireo Pharma Inc and its subsidiary Albireo AB and is affiliated with the Division of Translational Alzheimer Neurobiology, Karolinska Institute, Stockholm.
Job Titles:
- Business Development Director since 2023
Sebastian has 15 years of experience from pharmaceutical R&D and clinical development, CRO:s and GMP production of APIs (Active Pharmaceutical Ingredients). He has extensive experience in startups and business development. Before joining Alzinova he has been Chief Operating Officer at SWIPP AB, project manager and Key Account Manager at Polypeptide Group and Business development manager at Solve R&C.
Job Titles:
- Development Project Director since 2021
Stefan has 25 years experience of drug discovery and development. He has worked as a pre-clinical research manager and early clinical project leader to bring compounds for clinical testing and beyond. Stefan worked at AstraZeneca in different project leading and managerial roles in research and development. He also works as a senior consultant supporting smaller biotech and drug development companies.